NCT03311984Unknown不适用
Evaluation of Anti-Xa Levels in Critically Ill Patients Receiving Low-molecular-weight Heparin for Thromboprophylaxis in China
Southeast University, China1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2017年8月15日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 200
- 试验地点
- 1
- 主要终点
- Anti-Xa Levels
研究概览
简要总结
Critically ill Patients are at high risk to develop deep venous thrombosis. However, despite receiving of a standard dose of Low-molecular-weight Heparin（LMWH）, many patients still develop life-threatening embolism. The purpose of this study is to evaluate the anti-Xa levels of different dosing regimens of LMWH in critically ill patients in China.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult Critically ill patients
排除标准
- •Contraindication to use of LMWH. Intracranial bleeding/stroke, hematoma or bleeding disorder. Use Heparin anticoagulant therapy
结局指标
主要结局
Anti-Xa Levels
时间窗: six months
次要结局
未报告次要终点
研究者
Chun Pan
professor
Southeast University, China
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Influence of Vasopressors on Anti-Xa Activity in Critically Ill PatientsCritical IllnessThrombosisNCT06055907Medical University of Gdansk50
已完成
不适用
Anti-factor Xa Based Venous Thromboembolism ProphylaxisDose Adjustment of Enoxaparin in ICU PatientsNCT05221879Meir Medical Center75
已完成
不适用
Is Anti-Factor Xa Associated With Outcome in Patients With Critical COVID-19 on Low-Molecular-Weight Heparin?Covid19ThromboembolismBleedingNCT05256524Karolinska Institutet1,520
已完成
4 期
Pharmacokinetics of Enoxaparin in Intensive Care PatientsVenous ThromboembolismNCT02095509Tampere University Hospital39
招募中
不适用
Anti Xa Monitoring Low Molecular Weight Heparin on Prevention of Venous ThromboembolismVenous ThromboembolismNCT05382481Xuanwu Hospital, Beijing858